Drug firm Panacea Biotec today reported a net loss of Rs 71.72 crore for the quarter ended December 31, 2011, mainly due to delisting of the company's pentavalent vaccine by the World Health Organisation (WHO).
The company had posted a net profit of Rs 42.60 crore for the quarter ended December 31, 2010, Panacea Biotec said in a filing to Bombay Stock Exchange (BSE).
"The current performance continues to be affected due to the delisting of the pentavalent vaccine, following a routine site audit by a WHO team in July 2011," Panacea Biotec Joint Managing Director Rajesh Jain said.
Total income of the company stood at Rs 155.16 crore for the quarter under consideration. It was Rs 292.81 crore for the corresponding period in the previous fiscal.
Shares of Panacea Biotec today closed at Rs 89.05 on the BSE, up 0.56% from its previous close.
